Products
China Recombinant Hepatitis B Vaccine For Preventing HBV Infection Manufacturer, Supplier, Factory
AIM Honesty Biopharmaceutical Co., Ltd. is a professional China manufacturer providing Recombinant Hepatitis B Vaccine For Preventing HBV Infection. Based on advanced recombinant Hansenula polymorpha expression technology and patented adjuvant technology, the product offers a reliable hepatitis B immunization solution for newborns, healthcare workers, and other susceptible populations. The RECVAX® series has been applied for 20 years with nearly 500 million doses used.
Recombinant Hepatitis B Vaccine For Preventing HBV Infection is developed and manufactured by AIM Honesty Biopharmaceutical Co., Ltd., a professional vaccine manufacturer focusing on biological product innovation, research, development, and production. The product is based on an advanced recombinant Hansenula polymorpha expression technology platform and patented adjuvant technology, providing healthcare organizations and professional distributors with a stable solution for hepatitis B virus prevention.
For medical institutions, vaccine distributors, and public health organizations, preventing hepatitis B virus infection requires reliable immunization products supported by mature technology, consistent manufacturing capability, and practical application experience. Selecting a suitable vaccine supplier involves evaluating not only product specifications but also production background, quality management, and long-term cooperation capability.
AIM Honesty Biopharmaceutical Co., Ltd. independently developed the RECVAX® series based on the first domestic and internationally leading recombinant Hansenula polymorpha expression technology platform combined with patented adjuvant technology. Through continuous innovation in vaccine development and manufacturing, the company provides hepatitis B prevention solutions supported by long-term market application experience.
HBV Prevention Needs
Hepatitis B virus infection remains an important global health concern, and vaccination is a key strategy for reducing infection risks. For healthcare providers and vaccination programs, choosing an appropriate hepatitis B vaccine requires consideration of immune response, manufacturing reliability, and suitability for different populations.
The prevention of HBV infection depends on establishing effective immune protection through vaccination. A vaccine solution with established technology and application history can provide additional confidence for organizations responsible for immunization services.
When evaluating hepatitis B vaccine products, professional buyers usually focus on several important aspects:
1. Immunization performance: The ability of a vaccine technology platform to stimulate immune response is an important consideration.
2. Manufacturing consistency: Stable production processes help maintain reliable product characteristics.
3. Supplier experience: Long-term development and market application experience support professional cooperation.
Protection Application
Preventing HBV infection requires targeted immunization strategies for different groups. Hospitals, healthcare organizations, and vaccination programs need products that can support various prevention scenarios while maintaining stable supply and professional technical support.
| Population Group | Prevention Requirement |
| Newborns | Early hepatitis B immunization support, especially for newborns whose mothers are HBsAg and HBeAg positive |
| Healthcare Workers | Protection support for individuals with possible blood exposure risks in medical environments |
| Laboratory Personnel | Immunization consideration for professionals working with biological samples |
Recombinant Technology
Hansenula Polymorpha Expression System
The manufacturing technology used in hepatitis B vaccine production directly influences product development and quality management. Recombinant expression technology provides an advanced approach for producing vaccine antigens through controlled biological manufacturing processes.
The Hansenula polymorpha expression platform applied in RECVAX® represents an advanced recombinant technology route. This platform supports professional vaccine manufacturing by combining technical development experience with established production procedures.
Immune Response Support
Immune response is a key factor in vaccine evaluation. AIM Honesty Biopharmaceutical Co., Ltd. combines recombinant expression technology with patented adjuvant technology to improve immune stimulation characteristics.
The patented adjuvant technology uses in situ adsorption technology to create an "antigen bank" after administration. This approach helps maintain antigen release duration, extend antigen action time, and support immune response stimulation.
Long Term Experience
For vaccine procurement, long-term application experience provides important reference information. The RECVAX® series has been available on the market for 20 years, covering 31 provinces, cities, and autonomous regions in China, with total market usage reaching nearly 500 million doses.
This extensive application history reflects AIM Honesty Biopharmaceutical Co., Ltd.'s continuous focus on hepatitis B prevention and biological product manufacturing. It also provides healthcare partners with additional confidence when evaluating product stability and supplier capability.
Product Quality Specification
For healthcare organizations and professional buyers, product quality information is an important reference when evaluating vaccine suppliers. AIM Honesty Biopharmaceutical Co., Ltd. follows strict pharmacopeia standards during manufacturing and focuses on controlling key indicators related to product quality and consistency.
The following specification comparison provides reference information for different production systems based on important quality-related items.
| Pharmacopoeia Item | Endotoxin content | Free formaldehyde | Thiocyanate | Residual amount of antibiotics | Residual amount of bovine serum albumin |
| Hansenula polymorpha | Less than 5 EU/ml | Less than 15 µg/ml | Not applicable | Not applicable | Not applicable |
| Saccharomyces cerevisiae | Less than 5 EU/ml | Less than 20 µg/ml | Should be less than 1 µg/ml | Not applicable | Not applicable |
| CHO cells | Less than 10 EU/ml | Less than 50 µg/ml | Not applicable | No more than 50 ng/dose | No more than 50 ng/dose |
Expression Route Analysis
Different production technologies have different characteristics in terms of manufacturing process, quality control requirements, and application considerations. Understanding the technical background helps procurement teams make more suitable product evaluations.
| Process | Hansenula Yeast | Saccharomyces Yeast | CHO Cell |
| Process Description | Most advanced process | First generation yeast expression system | Most dated process |
| Tumorigenic Risk? | No | No | Yes |
| Antibiotic Added? | No | No | Yes |
| Bovine Serum Albumin Added? | No | No | Yes |
| Animal Pathogen Risk? | No | No | Yes |
| Thiocyanate Added? | No | Yes | No |
| Immunogenicity | High | Higher | Not much (general double dose vs. yeast shows poor response) |
| Vaccine Purity | Highest | Higher | More additives, lower purity |
| Potential Benefit | Strongest cellular immunity induction | Second strongest cellular immunity induction | Weakest cellular immunity induction |
| Representative Product Statement | 10 µg applicable to all populations | 10 µg applicable only to children | 10 µg immunogenicity poor, almost discontinued |
Buyer Evaluation Factors
For hospitals, distributors, and healthcare organizations, vaccine procurement involves evaluating multiple aspects beyond the product name. A professional supplier should provide stable manufacturing capability, transparent technical information, and long-term cooperation support.
| Evaluation Item | Why It Matters |
| Technology Background | Shows the manufacturing route and technical foundation behind the vaccine product |
| Market Application Experience | Provides reference for product maturity and practical usage |
| Quality Management | Helps ensure consistent product performance through controlled processes |
| Supply Capability | Supports continuous cooperation requirements of healthcare partners |
Application Scenario Overview
Preventing HBV infection requires suitable vaccination strategies according to different healthcare environments. The ecombinant Hepatitis B Vaccine For Preventing HBV Infection can support professional immunization applications where reliable hepatitis B prevention solutions are required.
| Application Scenario | Requirement Focus |
| Public Immunization Programs | Stable vaccine supply and reliable product information support |
| Hospital Vaccination Services | Product consistency and professional technical communication |
| Medical Distribution | Stable supplier cooperation and clear product specifications |
Manufacturing Capability
Stable manufacturing capability is an important factor for healthcare organizations when selecting vaccine suppliers. Biological products require professional production environments, experienced technical teams, and controlled manufacturing procedures to maintain consistent product quality.
AIM Honesty Biopharmaceutical Co., Ltd. focuses on vaccine research, development, and manufacturing. Through continuous improvement of production technology and management processes, the company supports the supply of hepatitis B vaccine products for professional healthcare applications.
The company's modern production workshops provide the foundation for professional vaccine manufacturing. Production capability, technical experience, and quality management work together to support reliable product development and long-term cooperation.
Production Process Control
Vaccine manufacturing requires strict attention to every stage of production. From technology application to final quality evaluation, each step plays an important role in maintaining product consistency.
| Process Stage | Control Focus |
| Technology Application | Using recombinant Hansenula polymorpha expression technology for vaccine development |
| Manufacturing Management | Maintaining controlled production procedures and technical consistency |
| Quality Evaluation | Checking important product indicators according to pharmacopeia requirements |
| Product Supply | Supporting professional healthcare partners with stable cooperation |
Quality Assurance
Quality management is a core part of vaccine manufacturing. For procurement organizations, understanding quality control practices helps evaluate supplier reliability and product suitability.
AIM Honesty Biopharmaceutical Co., Ltd. focuses on maintaining product quality through professional manufacturing management and evaluation procedures. The company pays attention to important indicators related to product characteristics and production requirements.
| Quality Management Area | Procurement Value |
| Product Consistency | Helps maintain stable characteristics between production batches |
| Technical Stability | Supports long-term application and supplier evaluation |
| Process Management | Provides a foundation for reliable biological product manufacturing |
Company Experience
AIM Honesty Biopharmaceutical Co., Ltd. has accumulated professional experience in ecombinant Hepatitis B Vaccine For Preventing HBV Infection development and manufacturing. The company focuses on biological products and continues to improve its technology capabilities and production systems.
The RECVAX® series has been available on the market for 20 years. According to the provided company information, the product has covered 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses.
This long-term application experience provides important reference for healthcare organizations evaluating vaccine suppliers. It reflects the company's continuous involvement in hepatitis B prevention and professional vaccine manufacturing.
Technology Application Value
The selection of vaccine technology influences product development, manufacturing characteristics, and application experience. The recombinant Hansenula polymorpha expression platform used by AIM Honesty Biopharmaceutical Co., Ltd. provides an advanced technical foundation for hepatitis B vaccine production.
Combined with patented adjuvant technology, the product development approach focuses on supporting immune stimulation and improving immunogenicity. This technology combination provides additional value for healthcare partners seeking reliable hepatitis B prevention solutions.
Professional Supply Support
For international healthcare partners, cooperation with a vaccine manufacturer requires clear communication, professional technical support, and stable production capability.
AIM Honesty Biopharmaceutical Co., Ltd. provides product information communication and cooperation support based on its experience in vaccine research and manufacturing. The company focuses on building long-term relationships with healthcare organizations, distributors, and professional partners.
Frequently Asked Questions
Q: What makes the recombinant Hansenula polymorpha technology different?
A: The recombinant Hansenula polymorpha expression platform is an advanced production technology route used for vaccine development. It provides a technical foundation for antigen production and supports professional vaccine manufacturing processes.
Q: Who may need hepatitis B vaccination support?
A: According to the provided product information, important application groups include newborns, especially those whose mothers are HBsAg and HBeAg positive, as well as healthcare workers and laboratory personnel who may experience blood exposure risks.
Q: How does AIM Honesty Biopharmaceutical Co., Ltd. support product quality?
A: AIM Honesty Biopharmaceutical Co., Ltd. focuses on quality management throughout vaccine development and manufacturing. The company evaluates important product indicators and follows pharmacopeia-related requirements to support product consistency.
Q: What information should healthcare organizations review before procurement?
A: Professional buyers usually review technology platform, product specifications, manufacturing capability, quality management information, and supplier experience before making procurement decisions.
Q: What role does patented adjuvant technology play in the product?
A: The patented adjuvant technology applies in situ adsorption technology to create an antigen bank after administration. This technology helps extend antigen action duration and supports immune response stimulation.
Q: Can this product support different healthcare application scenarios?
A: The product information indicates applications related to hepatitis B immunization needs, including newborn immunization, healthcare worker protection considerations, and professional vaccination services.
Q: What advantages does AIM Honesty Biopharmaceutical Co., Ltd. provide as a supplier?
A: AIM Honesty Biopharmaceutical Co., Ltd. combines vaccine research experience, recombinant technology development capability, and professional manufacturing systems to provide healthcare partners with product information support and cooperation services.
Conclusion
Preventing hepatitis B virus infection requires vaccine solutions supported by reliable technology, professional manufacturing capability, and long-term application experience. AIM Honesty Biopharmaceutical Co., Ltd. combines recombinant Hansenula polymorpha expression technology with patented adjuvant technology to provide a professional hepatitis B immunization solution for healthcare organizations and distribution partners.
With 20 years of market application experience and nearly 500 million doses used for the RECVAX® series, the company demonstrates continuous commitment to vaccine development and biological product manufacturing. For organizations seeking a stable and experienced supplier, Recombinant Hepatitis B Vaccine For Preventing HBV Infection provides a solution supported by established technology and professional production capabilities.
Related Products
Hot Products
Hepatitis B Vaccine for Newborns
To select a supplier for long-term cooperation and obtain highly protective Hepatitis B Vaccine for Newborns, you can contact AIM Honesty. The Hepatitis B birth dose vaccine is safe, affordable, and prevents a lifelong and potentially fatal infection, making it extremely important. We can provide a stable supply of reliable, high-quality vaccines.
Vaccines for Hajj
AIM Persistence Biopharmaceutical Co., Ltd. is a meningitis vaccine supplier from China. We provide vaccines for Hajj, offering high safety, long shelf life, and not just monovalent or bivalent meningococcal vaccines, but quadrivalent meningococcal vaccines, providing comprehensive coverage and all-around protection.
Vaccines for More Meningococcal Serotypes
AIM Persistence Biopharmaceutical Co., Ltd. is a professional vaccine manufacturer and supplier. We welcome you to obtain Vaccines for More Meningococcal Serotypes from us. Our Xin'er Cong® series products offer multiple serotypes, high seroconversion rates, low residual rates, and a long shelf life. We can provide a stable supply and are a reliable choice for long-term cooperation.
Anti-Hepatitis A Virus Vaccine
AIM Action Biopharmaceutical Co., Ltd. is a professional vaccine manufacturer. Our Anti-Hepatitis A Virus Vaccine is a preventive biological product prepared using modern biotechnology, strictly adhering to national pharmaceutical manufacturing quality management standards. It effectively stimulates the body to produce high-titer protective antibodies, thereby establishing an immune barrier against the hepatitis A virus.
W-Type Meningitis Vaccine
If you need a reliable supplier of W-Type Meningitis Vaccine, consider AIM Persistence Biopharmaceutical Co., Ltd. We are a Chinese company that develops vaccines using advanced domestic and international technologies. Our Xin'er Cong® series is an upgraded vaccine developed to address the threat of multiple serotypes of meningococcal meningitis, including W-type. It effectively prevents infection from four serotypes of meningococcal bacteria: A, C, Y, and W135 (W-type).
Booster Shot of Hepatitis B Vaccine
AIM Honesty Biopharmaceutical Co., Ltd. is a professional manufacturer and supplier of Booster Shot of Hepatitis B Vaccine. In addition to hepatitis B vaccines, we also provide hepatitis A vaccines, rabies vaccines, and more. We are a reliable partner with comprehensive R&D capabilities. Our vaccines utilize advanced technology and are safe and effective.
- Related Blog
- Reviews
